West Pharmaceutical Services Inc
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; sy… Read more
West Pharmaceutical Services Inc (WST) - Net Assets
Latest net assets as of December 2025: $3.18 Billion USD
Based on the latest financial reports, West Pharmaceutical Services Inc (WST) has net assets worth $3.18 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.27 Billion) and total liabilities ($1.09 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.18 Billion |
| % of Total Assets | 74.38% |
| Annual Growth Rate | 8.55% |
| 5-Year Change | 35.99% |
| 10-Year Change | 184.21% |
| Growth Volatility | 16.34 |
West Pharmaceutical Services Inc - Net Assets Trend (1985–2025)
This chart illustrates how West Pharmaceutical Services Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for West Pharmaceutical Services Inc (1985–2025)
The table below shows the annual net assets of West Pharmaceutical Services Inc from 1985 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $3.18 Billion | +18.41% |
| 2024-12-31 | $2.68 Billion | -6.90% |
| 2023-12-31 | $2.88 Billion | +7.30% |
| 2022-12-31 | $2.68 Billion | +14.97% |
| 2021-12-31 | $2.34 Billion | +25.93% |
| 2020-12-31 | $1.85 Billion | +17.88% |
| 2019-12-31 | $1.57 Billion | +55.79% |
| 2018-12-31 | $1.01 Billion | -39.38% |
| 2017-12-31 | $1.67 Billion | +49.06% |
| 2016-12-31 | $1.12 Billion | +9.14% |
| 2015-12-31 | $1.02 Billion | +6.87% |
| 2014-12-31 | $958.10 Million | +5.70% |
| 2013-12-31 | $906.40 Million | +24.35% |
| 2012-12-31 | $728.90 Million | +11.30% |
| 2011-12-31 | $654.90 Million | +4.67% |
| 2010-12-31 | $625.70 Million | +8.05% |
| 2009-12-31 | $579.10 Million | +18.89% |
| 2008-12-31 | $487.10 Million | -0.77% |
| 2007-12-31 | $490.90 Million | +17.08% |
| 2006-12-31 | $419.30 Million | +25.50% |
| 2005-12-31 | $334.10 Million | +7.57% |
| 2004-12-31 | $310.60 Million | +20.57% |
| 2003-12-31 | $257.60 Million | +23.43% |
| 2002-12-31 | $208.70 Million | +18.04% |
| 2001-12-31 | $176.80 Million | -17.42% |
| 2000-12-31 | $214.10 Million | -7.72% |
| 1999-12-31 | $232.00 Million | +1.67% |
| 1998-12-31 | $228.20 Million | -17.94% |
| 1997-12-31 | $278.10 Million | +10.23% |
| 1996-12-31 | $252.30 Million | -0.79% |
| 1995-12-31 | $254.30 Million | +10.95% |
| 1994-12-31 | $229.20 Million | +15.18% |
| 1993-12-31 | $199.00 Million | +11.36% |
| 1992-12-31 | $178.70 Million | +10.92% |
| 1991-12-31 | $161.10 Million | -14.22% |
| 1990-12-31 | $187.80 Million | -0.53% |
| 1989-12-31 | $188.80 Million | +10.15% |
| 1988-12-31 | $171.40 Million | +10.01% |
| 1987-12-31 | $155.80 Million | +12.17% |
| 1986-12-31 | $138.90 Million | +16.23% |
| 1985-12-31 | $119.50 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to West Pharmaceutical Services Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3757.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $4.37 Billion | 137.75% |
| Common Stock | $18.80 Million | 0.59% |
| Other Comprehensive Income | $-105.50 Million | -3.32% |
| Total Equity | $3.18 Billion | 100.00% |
West Pharmaceutical Services Inc Competitors by Market Cap
The table below lists competitors of West Pharmaceutical Services Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sandoz Group AG
OTCQX:SDZXF
|
$17.13 Billion |
|
Las Vegas Sands Corp
NYSE:LVS
|
$17.15 Billion |
|
HP Inc
NYSE:HPQ
|
$17.15 Billion |
|
Lululemon Athletica Inc.
NASDAQ:LULU
|
$17.16 Billion |
|
Tyson Foods Inc
NYSE:TSN
|
$17.12 Billion |
|
Novonesis (Novozymes) A/S
CO:NSIS-B
|
$17.10 Billion |
|
Centene Corp
NYSE:CNC
|
$17.10 Billion |
|
Yum China Holdings Inc
NYSE:YUMC
|
$17.08 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in West Pharmaceutical Services Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,682,300,000 to 3,176,000,000, a change of 493,700,000 (18.4%).
- Net income of 493,700,000 contributed positively to equity growth.
- Dividend payments of 61,200,000 reduced retained earnings.
- Share repurchases of 134,000,000 reduced equity.
- Other comprehensive income increased equity by 152,600,000.
- Other factors increased equity by 42,600,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $493.70 Million | +15.54% |
| Dividends Paid | $61.20 Million | -1.93% |
| Share Repurchases | $134.00 Million | -4.22% |
| Other Comprehensive Income | $152.60 Million | +4.8% |
| Other Changes | $42.60 Million | +1.34% |
| Total Change | $- | 18.41% |
Book Value vs Market Value Analysis
This analysis compares West Pharmaceutical Services Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.48x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 126.54x to 5.48x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1985-12-31 | $1.89 | $239.42 | x |
| 1986-12-31 | $2.17 | $239.42 | x |
| 1987-12-31 | $2.42 | $239.42 | x |
| 1988-12-31 | $2.64 | $239.42 | x |
| 1989-12-31 | $2.76 | $239.42 | x |
| 1990-12-31 | $2.76 | $239.42 | x |
| 1991-12-31 | $2.47 | $239.42 | x |
| 1992-12-31 | $2.67 | $239.42 | x |
| 1993-12-31 | $2.94 | $239.42 | x |
| 1994-12-31 | $3.54 | $239.42 | x |
| 1995-12-31 | $3.84 | $239.42 | x |
| 1996-12-31 | $3.84 | $239.42 | x |
| 1997-12-31 | $4.19 | $239.42 | x |
| 1998-12-31 | $3.49 | $239.42 | x |
| 1999-12-31 | $3.84 | $239.42 | x |
| 2000-12-31 | $3.55 | $239.42 | x |
| 2001-12-31 | $3.08 | $239.42 | x |
| 2002-12-31 | $3.49 | $239.42 | x |
| 2003-12-31 | $4.43 | $239.42 | x |
| 2004-12-31 | $4.89 | $239.42 | x |
| 2005-12-31 | $5.13 | $239.42 | x |
| 2006-12-31 | $6.17 | $239.42 | x |
| 2007-12-31 | $6.70 | $239.42 | x |
| 2008-12-31 | $6.75 | $239.42 | x |
| 2009-12-31 | $7.98 | $239.42 | x |
| 2010-12-31 | $8.52 | $239.42 | x |
| 2011-12-31 | $8.85 | $239.42 | x |
| 2012-12-31 | $10.15 | $239.42 | x |
| 2013-12-31 | $12.69 | $239.42 | x |
| 2014-12-31 | $13.14 | $239.42 | x |
| 2015-12-31 | $13.87 | $239.42 | x |
| 2016-12-31 | $14.90 | $239.42 | x |
| 2017-12-31 | $16.89 | $239.42 | x |
| 2018-12-31 | $18.52 | $239.42 | x |
| 2019-12-31 | $20.86 | $239.42 | x |
| 2020-12-31 | $24.47 | $239.42 | x |
| 2021-12-31 | $30.61 | $239.42 | x |
| 2022-12-31 | $35.42 | $239.42 | x |
| 2023-12-31 | $38.26 | $239.42 | x |
| 2024-12-31 | $36.39 | $239.42 | x |
| 2025-12-31 | $43.69 | $239.42 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently West Pharmaceutical Services Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.54%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.06%
- • Asset Turnover: 0.72x
- • Equity Multiplier: 1.34x
- Recent ROE (15.54%) is above the historical average (11.91%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1985 | 12.55% | 7.89% | 1.06x | 1.50x | $3.05 Million |
| 1986 | 12.24% | 7.22% | 0.99x | 1.71x | $3.11 Million |
| 1987 | 8.79% | 5.41% | 0.90x | 1.80x | $-1.88 Million |
| 1988 | 10.15% | 6.04% | 0.96x | 1.74x | $260.00K |
| 1989 | 11.52% | 6.71% | 0.99x | 1.74x | $2.73 Million |
| 1990 | 2.44% | 1.33% | 0.94x | 1.95x | $-13.31 Million |
| 1991 | -5.57% | -2.58% | 1.05x | 2.05x | $-23.77 Million |
| 1992 | 11.68% | 5.82% | 1.11x | 1.81x | $2.84 Million |
| 1993 | 12.49% | 6.74% | 1.13x | 1.63x | $4.69 Million |
| 1994 | 12.01% | 7.48% | 0.92x | 1.75x | $4.57 Million |
| 1995 | 11.29% | 6.95% | 0.86x | 1.89x | $3.29 Million |
| 1996 | 6.51% | 3.57% | 0.96x | 1.89x | $-8.80 Million |
| 1997 | 15.99% | 9.81% | 0.95x | 1.72x | $16.63 Million |
| 1998 | 2.91% | 1.49% | 0.89x | 2.20x | $-16.31 Million |
| 1999 | 16.74% | 8.25% | 0.85x | 2.39x | $15.58 Million |
| 2000 | 0.78% | 0.37% | 0.77x | 2.72x | $-18.88 Million |
| 2001 | -2.94% | -1.31% | 0.78x | 2.89x | $-22.88 Million |
| 2002 | 9.13% | 4.38% | 0.78x | 2.66x | $-1.75 Million |
| 2003 | 12.38% | 6.50% | 0.79x | 2.42x | $6.14 Million |
| 2004 | 6.44% | 3.58% | 0.82x | 2.19x | $-10.71 Million |
| 2005 | 13.67% | 6.52% | 0.85x | 2.47x | $12.25 Million |
| 2006 | 16.19% | 7.35% | 0.99x | 2.22x | $25.65 Million |
| 2007 | 14.57% | 6.93% | 0.86x | 2.44x | $22.17 Million |
| 2008 | 17.66% | 8.18% | 0.90x | 2.40x | $37.29 Million |
| 2009 | 12.54% | 6.88% | 0.83x | 2.19x | $14.69 Million |
| 2010 | 10.44% | 5.91% | 0.85x | 2.07x | $2.73 Million |
| 2011 | 11.53% | 6.33% | 0.85x | 2.14x | $10.01 Million |
| 2012 | 11.07% | 6.37% | 0.81x | 2.15x | $7.81 Million |
| 2013 | 12.39% | 8.21% | 0.82x | 1.84x | $21.66 Million |
| 2014 | 13.28% | 8.94% | 0.85x | 1.75x | $31.41 Million |
| 2015 | 9.34% | 6.83% | 0.83x | 1.66x | $-6.79 Million |
| 2016 | 12.85% | 9.52% | 0.88x | 1.54x | $31.85 Million |
| 2017 | 11.77% | 9.42% | 0.86x | 1.46x | $22.71 Million |
| 2018 | 14.82% | 12.04% | 1.08x | 1.14x | $67.27 Million |
| 2019 | 15.36% | 13.11% | 0.79x | 1.49x | $84.38 Million |
| 2020 | 18.67% | 16.13% | 0.77x | 1.51x | $160.75 Million |
| 2021 | 28.34% | 23.38% | 0.85x | 1.42x | $428.26 Million |
| 2022 | 21.82% | 20.30% | 0.80x | 1.35x | $317.41 Million |
| 2023 | 20.60% | 20.11% | 0.77x | 1.33x | $305.30 Million |
| 2024 | 18.37% | 17.03% | 0.79x | 1.36x | $224.47 Million |
| 2025 | 15.54% | 16.06% | 0.72x | 1.34x | $176.10 Million |
Industry Comparison
This section compares West Pharmaceutical Services Inc's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,683,526,542
- Average return on equity (ROE) among peers: -32.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| West Pharmaceutical Services Inc (WST) | $3.18 Billion | 12.55% | 0.34x | $17.12 Billion |
| ANGELALIGN TECHNOLOGY INC (AGLFF) | $480.24 Million | 2.52% | 0.41x | $405.57 Million |
| Akoya Biosciences Inc (AKYA) | $-30.16 Million | 0.00% | 0.00x | $16.24 Million |
| Alcon AG (ALC) | $19.68 Billion | 1.70% | 0.48x | $37.82 Billion |
| Align Technology Inc (ALGN) | $3.85 Billion | 10.94% | 0.61x | $11.75 Billion |
| AngioDynamics Inc (ANGO) | $355.71 Million | 3.06% | 0.15x | $354.40 Million |
| Ansell Limited (ANSLF) | $386.33 Million | -0.45% | 0.87x | $2.58 Billion |
| AptarGroup Inc (ATR) | $2.07 Billion | 11.57% | 1.03x | $8.27 Billion |
| AtriCure Inc (ATRC) | $72.60 Million | -15.79% | 0.54x | $1.42 Billion |
| Avinger Inc (AVGR) | $-35.69 Million | 0.00% | 0.00x | $1.26 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $9.03 Million | -338.35% | 0.77x | $156.14 Million |